{"id":19263,"date":"2019-05-13T13:50:00","date_gmt":"2019-05-13T21:50:00","guid":{"rendered":"https:\/\/associatednews.info\/content\/states-sue-drugmakers-over-alleged-generic-price-fixing-scheme\/"},"modified":"2019-05-13T13:50:00","modified_gmt":"2019-05-13T21:50:00","slug":"states-sue-drugmakers-over-alleged-generic-price-fixing-scheme","status":"publish","type":"post","link":"https:\/\/associatednews.info\/content\/states-sue-drugmakers-over-alleged-generic-price-fixing-scheme\/","title":{"rendered":"States Sue Drugmakers Over Alleged Generic-Price-Fixing Scheme"},"content":{"rendered":"<p><span style=\"font-style:italic;font-size:16px\">By  <a target=\"_blank\" href=\"https:\/\/www.npr.org\/sections\/health-shots\/2019\/05\/13\/722881642\/states-sue-drugmakers-over-alleged-generic-price-fixing-scheme?utm_medium=RSS&amp;utm_campaign=healthcare\" rel=\"nofollow&quot; noopener noreferrer\">Selena Simmons-Duffin<\/a><\/span>  <\/p>\n<div class=\"ftpimagefix\" style=\"float:left\"><a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.npr.org\/sections\/health-shots\/2019\/05\/13\/722881642\/states-sue-drugmakers-over-alleged-generic-price-fixing-scheme?utm_medium=RSS&amp;utm_campaign=healthcare\"><img decoding=\"async\" width=\"150\" src=\"https:\/\/media.npr.org\/assets\/img\/2019\/05\/13\/heaps-of-pills-gettyimages-826753434-a8b8c5a4249cb5a198d816571d99e69c9f9096bc-s800-c15.jpg\" data-original=\"https:\/\/media.npr.org\/assets\/img\/2019\/05\/13\/heaps-of-pills-gettyimages-826753434-a8b8c5a4249cb5a198d816571d99e69c9f9096bc-s800.jpg\" alt=\"An assortment of drugs.\"><\/a><\/div>\n<div>\n<div data-crop-type>\n<div>\n            <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/media.npr.org\/assets\/img\/2019\/05\/13\/heaps-of-pills-gettyimages-826753434-a8b8c5a4249cb5a198d816571d99e69c9f9096bc-s1200.jpg\">Enlarge this image<\/a>\n        <\/div>\n<\/div>\n<div>\n<div>\n<div aria-label=\"Image caption\">\n        <\/div>\n<\/p><\/div>\n<p>    <span aria-label=\"Image credit\"><\/p>\n<p>        Jose A. Bernat Bacete\/Getty Images<\/p>\n<p>    <\/span>\n<\/div>\n<\/p><\/div>\n<p>Connecticut Attorney General William Tong has a skin condition called rosacea, and <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.facebook.com\/WFSB3\/videos\/680852205679361\/\">he says<\/a> he takes the antibiotic doxycycline once a day for it. <\/p>\n<p>In 2013, the <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.sanders.senate.gov\/download\/letter-to-mr-saunders-ceo-and-president-actavis?inline=file\">average market price<\/a> of doxycycline rose from $20 to $1,829 a year later. That&#8217;s an increase of over 8,000%.<\/p>\n<p>Tong alleges in <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/portal.ct.gov\/-\/media\/AG\/Downloads\/GDMS%20Complaint%2051019%20FINAL%20REDACTED%20PUBLIC%20VERSIONpdf\">a new lawsuit<\/a> that this kind of price jump is part of an industrywide conspiracy to fix prices. <\/p>\n<p>The suit is a whopper  \u2014  at least 43 states are suing 20 companies, and the document is over 500 pages long. It was filed Friday in the U.S. District Court in Connecticut.<\/p>\n<p>The lawsuit alleges that sometimes one company would decide to raise prices on a particular drug, and other companies would follow suit. Other times, companies would agree to divide up the market rather than competing for market share by lowering prices. <\/p>\n<p>It says these kind of activities have been happening for years and that companies would avoid creating evidence by making these agreements on golf outings or during &#8220;girls nights outs&#8221; or over text message. <\/p>\n<p>In several examples, the suit cites call logs between executives at different companies, showing a flurry of phone calls right before several companies would all raise prices in lockstep. <\/p>\n<aside aria-label=\"advertisement\">\n<div data-ad-config='{\"network\":\"\/6735\/n6735\",\"site\":{\"default\":\"NPR\",\"mobile\":\"NPRMOBILE\"},\"zone\":\"News_Health_Health_Care\",\"targets\":{\"testserver\":\"false\",\"storyId\":\"722881642\",\"program\":\"All_Things_Considered\",\"agg\":[\"693693672\",\"336818857\",\"155111283\",\"191676894\",\"434975886\",\"103537970\"],\"blog\":\"103537970\"},\"location\":\"backstage\",\"deferred\":false,\"isBetweenContent\":true,\"isAggSponsorship\":false,\"borderClass\":\"\"}'><\/div>\n<\/aside>\n<p>All of this, according to the lawsuit, resulted &#8220;in many billions of dollars of harm to the national economy.&#8221;<\/p>\n<div>\n<div data-crop-type>\n    <img decoding=\"async\" src=\"https:\/\/media.npr.org\/assets\/img\/2019\/05\/13\/190513_tong_generic_suit-1-frankie-grazian-connecticut-public-radio-00074f52ef7ac57130a43516c0b61de7de3b7d3d-s800-c15.jpg\" data-original=\"https:\/\/media.npr.org\/assets\/img\/2019\/05\/13\/190513_tong_generic_suit-1-frankie-grazian-connecticut-public-radio-00074f52ef7ac57130a43516c0b61de7de3b7d3d-s800.jpg\" alt><\/p>\n<div>\n            <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/media.npr.org\/assets\/img\/2019\/05\/13\/190513_tong_generic_suit-1-frankie-grazian-connecticut-public-radio-00074f52ef7ac57130a43516c0b61de7de3b7d3d-s1200.jpg\">Enlarge this image<\/a>\n        <\/div>\n<\/div>\n<div>\n<div>\n<div aria-label=\"Image caption\">\n<p>\n                Connecticut Attorney General William Tong says the generic drug industry is profiting &#8220;in a highly illegal way&#8221; from Americans. Tong is at the forefront of a multistate lawsuit filed May 10 that alleges companies worked together to set prices.<\/p>\n<p>                <b aria-label=\"Image credit\"><\/p>\n<p>                    Frankie Grazian\/Connecticut Public Radio<\/p>\n<p>                <\/b><br \/>\n                <b><b>hide caption<\/b><\/b>\n            <\/p>\n<\/p><\/div>\n<p>            <b><b>toggle caption<\/b><\/b>\n    <\/div>\n<p>    <span aria-label=\"Image credit\"><\/p>\n<p>        Frankie Grazian\/Connecticut Public Radio<\/p>\n<p>    <\/span>\n<\/div>\n<\/p><\/div>\n<p>Consumers don&#8217;t always notice when a generic drug&#8217;s price increases rapidly. People without insurance, of course, pay full price, but even people with insurance can feel the impact.<\/p>\n<p>&#8220;More people than ever before are paying based on the price of the drugs,&#8221; explains <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.vumc.org\/health-policy\/person\/stacie-b-dusetzina-phd\">Stacie Dusetzina<\/a>, a professor at Vanderbilt University who studies drug pricing. Often, patients have to meet a deductible before their health plan&#8217;s coverage kicks in, so &#8220;they pay full price until they reach a certain level of spending, or they pay a percentage of the drug&#8217;s price  \u2014  we call that a coinsurance.&#8221; <\/p>\n<p>Surveys show more Americans are <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.kff.org\/private-insurance\/press-release\/kff-los-angeles-times-survey-highlights-financial-challenges-facing-people-with-employer-health-benefits\/\">having trouble<\/a> paying out-of-pocket medical costs. The average annual deductible in job-based health plans has <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.latimes.com\/politics\/la-na-pol-health-insurance-medical-bills-20190502-story.html\">quadrupled <\/a>in the past 12 years and now averages $1,300. <\/p>\n<p>But, Dusetzina says, even if you only pay a modest copay \u2014 such as $5 for every prescription you pick up \u2014 if your insurance company is paying more for prescription drugs, it can raise your health plan&#8217;s premiums the following year. &#8220;So ultimately these costs do get borne by the consumer in some way,&#8221; she says.<\/p>\n<p>Dusetzina says what this lawsuit alleges is &#8220;very disappointing&#8221; \u2014 a situation in which consumers put up with the high price of branded drugs because of the implicit promise that a generic is coming some day and will eventually bring the price down. <\/p>\n<p>But that outcome doesn&#8217;t happen automatically; it relies on healthy competition and market forces to work. If there&#8217;s only one generic version available, that drugmaker can set the price at pretty much the same level as the brand name. <\/p>\n<p>&#8220;The higher the number of competitors, the more we see price reductions from the branded drug price,&#8221; she says. &#8220;So the magic number seems to be around four manufacturers.&#8221;<\/p>\n<p>And that assumes those drugmakers aren&#8217;t talking to each other and agreeing to coordinate rather than compete.<\/p>\n<p>The main drugmaker cited in the lawsuit is <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.tevapharm.com\/\">Teva<\/a>, an Israeli company. In a statement, Kelley Dougherty, vice president of communications and brand, Teva North America, told NPR that the company is reviewing the allegations internally and that Teva &#8220;has not engaged in any conduct that would lead to civil or criminal liability.&#8221; <\/p>\n<p>The company has also asserted that there&#8217;s <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/en.globes.co.il\/en\/article-teva-cfo-well-defend-ourselves-vigorously-1001285203\">nothing new here<\/a>. It&#8217;s true that the new lawsuit is similar to <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/s3.amazonaws.com\/assets.fiercemarkets.net\/public\/004-Healthcare\/external_Q32018\/HumanaVActavis.pdf\">past lawsuits<\/a>, though none of them included so many states as plaintiffs. <\/p>\n<p>Tong has emphasized that the investigation is ongoing. Given the amount of political appetite there is to bring drug prices down, there are certainly more lawsuits to come.<\/p>\n<p><strong><a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/blockads.fivefilters.org\/\">Let&#8217;s block ads!<\/a><\/strong> <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/blockads.fivefilters.org\/acceptable.html\">(Why?)<\/a><\/p>\n<p>Source:: <a href=\"https:\/\/www.npr.org\/sections\/health-shots\/2019\/05\/13\/722881642\/states-sue-drugmakers-over-alleged-generic-price-fixing-scheme?utm_medium=RSS&amp;utm_campaign=healthcare\" target=\"_blank\" title=\"States Sue Drugmakers Over Alleged Generic-Price-Fixing Scheme\" rel=\"nofollow noopener noreferrer\">https:\/\/www.npr.org\/sections\/health-shots\/2019\/05\/13\/722881642\/states-sue-drugmakers-over-alleged-generic-price-fixing-scheme?utm_medium=RSS&amp;utm_campaign=healthcare<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<div class=\"ftpimagefix\" style=\"float:left\"><a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.npr.org\/sections\/health-shots\/2019\/05\/13\/722881642\/states-sue-drugmakers-over-alleged-generic-price-fixing-scheme?utm_medium=RSS&amp;utm_campaign=healthcare\"><img decoding=\"async\" width=\"150\" src=\"https:\/\/media.npr.org\/assets\/img\/2019\/05\/13\/heaps-of-pills-gettyimages-826753434-a8b8c5a4249cb5a198d816571d99e69c9f9096bc-s800-c15.jpg\" data-original=\"https:\/\/media.npr.org\/assets\/img\/2019\/05\/13\/heaps-of-pills-gettyimages-826753434-a8b8c5a4249cb5a198d816571d99e69c9f9096bc-s800.jpg\" alt=\"An assortment of drugs.\"><\/a><\/div>\n<div>\n<div data-crop-type>\n<div>\n            <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/media.npr.org\/assets\/img\/2019\/05\/13\/heaps-of-pills-gettyimages-826753434-a8b8c5a4249cb5a198d816571d99e69c9f9096bc-s1200.jpg\">Enlarge this image<\/a>\n        <\/div>\n<\/div>\n<div>\n<div>\n<div aria-label=\"Image caption\">\n        <\/div>\n<\/p><\/div>\n<p>    <span aria-label=\"Image credit\"><\/p>\n<p>        Jose A. Bernat Bacete\/Getty Images<\/p>\n<p>    <\/span>\n<\/div>\n<\/p><\/div>\n<p>Connecticut Attorney General William Tong has a skin condition called rosacea, and <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.facebook.com\/WFSB3\/videos\/680852205679361\/\">he says<\/a> he takes the antibiotic doxycycline once a day for it. <\/p>\n<p>In 2013, the <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.sanders.senate.gov\/download\/letter-to-mr-saunders-ceo-and-president-actavis?inline=file\">average market price<\/a> of doxycycline rose from $20 to $1,829 a year later. That&#8217;s an increase of over 8,000%.<\/p>\n<p>Tong alleges in <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/portal.ct.gov\/-\/media\/AG\/Downloads\/GDMS%20Complaint%2051019%20FINAL%20REDACTED%20PUBLIC%20VERSIONpdf\">a new lawsuit<\/a> that this kind of price jump is part of an industrywide conspiracy to fix prices. <\/p>\n<p>The suit is a whopper  \u2014  at least 43 states are suing 20 companies, and the document is over 500 pages long. It was filed Friday in the U.S. District Court in Connecticut.<\/p>\n<p>The lawsuit alleges that sometimes one company would decide to raise prices on a particular drug, and other companies would follow suit. Other times, companies would agree to divide up the market rather than competing for market share by lowering prices. <\/p>\n<p>It says these kind of activities have been happening for years and that companies would avoid creating evidence by making these agreements on golf outings or during &#8220;girls nights outs&#8221; or over text message. <\/p>\n<p>In several examples, the suit cites call logs between executives at different companies, showing a flurry of phone calls right before several companies would all raise prices in lockstep. <\/p>\n<aside aria-label=\"advertisement\">\n<div data-ad-config='{\"network\":\"\/6735\/n6735\",\"site\":{\"default\":\"NPR\",\"mobile\":\"NPRMOBILE\"},\"zone\":\"News_Health_Health_Care\",\"targets\":{\"testserver\":\"false\",\"storyId\":\"722881642\",\"program\":\"All_Things_Considered\",\"agg\":[\"693693672\",\"336818857\",\"155111283\",\"191676894\",\"434975886\",\"103537970\"],\"blog\":\"103537970\"},\"location\":\"backstage\",\"deferred\":false,\"isBetweenContent\":true,\"isAggSponsorship\":false,\"borderClass\":\"\"}'><\/div>\n<\/aside>\n<p>All of this, according to the lawsuit, resulted &#8220;in many billions of dollars of harm to the national economy.&#8221;<\/p>\n<div>\n<div data-crop-type>\n    <img decoding=\"async\" src=\"https:\/\/media.npr.org\/assets\/img\/2019\/05\/13\/190513_tong_generic_suit-1-frankie-grazian-connecticut-public-radio-00074f52ef7ac57130a43516c0b61de7de3b7d3d-s800-c15.jpg\" data-original=\"https:\/\/media.npr.org\/assets\/img\/2019\/05\/13\/190513_tong_generic_suit-1-frankie-grazian-connecticut-public-radio-00074f52ef7ac57130a43516c0b61de7de3b7d3d-s800.jpg\" alt><\/p>\n<div>\n            <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/media.npr.org\/assets\/img\/2019\/05\/13\/190513_tong_generic_suit-1-frankie-grazian-connecticut-public-radio-00074f52ef7ac57130a43516c0b61de7de3b7d3d-s1200.jpg\">Enlarge this image<\/a>\n        <\/div>\n<\/div>\n<div>\n<div>\n<div aria-label=\"Image caption\">\n<p>\n                Connecticut Attorney General William Tong says the generic drug industry is profiting &#8220;in a highly illegal way&#8221; from Americans. Tong is at the forefront of a multistate lawsuit filed May 10 that alleges companies worked together to set prices.<\/p>\n<p>                <b aria-label=\"Image credit\"><\/p>\n<p>                    Frankie Grazian\/Connecticut Public Radio<\/p>\n<p>                <\/b><br \/>\n                <b><b>hide caption<\/b><\/b>\n            <\/p>\n<\/p><\/div>\n<p>            <b><b>toggle caption<\/b><\/b>\n    <\/div>\n<p>    <span aria-label=\"Image credit\"><\/p>\n<p>        Frankie Grazian\/Connecticut Public Radio<\/p>\n<p>    <\/span>\n<\/div>\n<\/p><\/div>\n<p>Consumers don&#8217;t always notice when a generic drug&#8217;s price increases rapidly. People without insurance, of course, pay full price, but even people with insurance can feel the impact.<\/p>\n<p>&#8220;More people than ever before are paying based on the price of the drugs,&#8221; explains <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.vumc.org\/health-policy\/person\/stacie-b-dusetzina-phd\">Stacie Dusetzina<\/a>, a professor at Vanderbilt University who studies drug pricing. Often, patients have to meet a deductible before their health plan&#8217;s coverage kicks in, so &#8220;they pay full price until they reach a certain level of spending, or they pay a percentage of the drug&#8217;s price  \u2014  we call that a coinsurance.&#8221; <\/p>\n<p>Surveys show more Americans are <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.kff.org\/private-insurance\/press-release\/kff-los-angeles-times-survey-highlights-financial-challenges-facing-people-with-employer-health-benefits\/\">having trouble<\/a> paying out-of-pocket medical costs. The average annual deductible in job-based health plans has <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.latimes.com\/politics\/la-na-pol-health-insurance-medical-bills-20190502-story.html\">quadrupled <\/a>in the past 12 years and now averages $1,300. <\/p>\n<p>But, Dusetzina says, even if you only pay a modest copay \u2014 such as $5 for every prescription you pick up \u2014 if your insurance company is paying more for prescription drugs, it can raise your health plan&#8217;s premiums the following year. &#8220;So ultimately these costs do get borne by the consumer in some way,&#8221; she says.<\/p>\n<p>Dusetzina says what this lawsuit alleges is &#8220;very disappointing&#8221; \u2014 a situation in which consumers put up with the high price of branded drugs because of the implicit promise that a generic is coming some day and will eventually bring the price down. <\/p>\n<p>But that outcome doesn&#8217;t happen automatically; it relies on healthy competition and market forces to work. If there&#8217;s only one generic version available, that drugmaker can set the price at pretty much the same level as the brand name. <\/p>\n<p>&#8220;The higher the number of competitors, the more we see price reductions from the branded drug price,&#8221; she says. &#8220;So the magic number seems to be around four manufacturers.&#8221;<\/p>\n<p>And that assumes those drugmakers aren&#8217;t talking to each other and agreeing to coordinate rather than compete.<\/p>\n<p>The main drugmaker cited in the lawsuit is <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/www.tevapharm.com\/\">Teva<\/a>, an Israeli company. In a statement, Kelley Dougherty, vice president of communications and brand, Teva North America, told NPR that the company is reviewing the allegations internally and that Teva &#8220;has not engaged in any conduct that would lead to civil or criminal liability.&#8221; <\/p>\n<p>The company has also asserted that there&#8217;s <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/en.globes.co.il\/en\/article-teva-cfo-well-defend-ourselves-vigorously-1001285203\">nothing new here<\/a>. It&#8217;s true that the new lawsuit is similar to <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/s3.amazonaws.com\/assets.fiercemarkets.net\/public\/004-Healthcare\/external_Q32018\/HumanaVActavis.pdf\">past lawsuits<\/a>, though none of them included so many states as plaintiffs. <\/p>\n<p>Tong has emphasized that the investigation is ongoing. Given the amount of political appetite there is to bring drug prices down, there are certainly more lawsuits to come.<\/p>\n<p><strong><a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/blockads.fivefilters.org\/\">Let&#8217;s block ads!<\/a><\/strong> <a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"https:\/\/blockads.fivefilters.org\/acceptable.html\">(Why?)<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-19263","post","type-post","status-publish","format-standard","hentry","category-health"],"_links":{"self":[{"href":"https:\/\/associatednews.info\/content\/wp-json\/wp\/v2\/posts\/19263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/associatednews.info\/content\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/associatednews.info\/content\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/associatednews.info\/content\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/associatednews.info\/content\/wp-json\/wp\/v2\/comments?post=19263"}],"version-history":[{"count":0,"href":"https:\/\/associatednews.info\/content\/wp-json\/wp\/v2\/posts\/19263\/revisions"}],"wp:attachment":[{"href":"https:\/\/associatednews.info\/content\/wp-json\/wp\/v2\/media?parent=19263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/associatednews.info\/content\/wp-json\/wp\/v2\/categories?post=19263"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/associatednews.info\/content\/wp-json\/wp\/v2\/tags?post=19263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}